# Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma

> **NCT02594163** · PHASE2 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 25 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma Refractory
- Follicular B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Brentuximab Vedotin
- **DRUG:** Rituximab
- **DRUG:** Bendamustine

## Key facts

- **NCT ID:** NCT02594163
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-10
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Sponsor decision based on portfolio prioritization
- **Last updated:** 2018-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02594163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02594163, "Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02594163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*